Dr. Dabaja focuses his research on Chimeric Antigen Receptor T-cell Therapy (CAR T), haploidentical transplantation, reduced intensity conditioning regimens for lymphoid malignancies, vaccine therapy for CMV in the setting of allogeneic HCT, graft versus host disease (acute and chronic), personalized cancer care using genomics in hematopoietic cell transplantation, and evidence-based medicine in hematopoietic cell transplantation.